Braillon A, Calès P, Lebrec D
Int J Clin Pharmacol Res. 1985;5(4):223-8.
The splanchnic and systemic haemodynamic effects of mepindolol (0.6 mg, IV), a beta-blocker with a marked beta 2-blockade activity and propranolol (15 mg, IV) were studied in two groups of eight patients with portal hypertension due to cirrhosis. Similar decreases in the hepatic venous pressure gradient were observed after mepindolol and propranolol, whereas hepatic blood flow significantly decreased after mepindolol but did not significantly do so after propranolol. The decreases in cardiac output and heart rate were statistically significant and similar after mepindolol and propranolol. Mepindolol slightly decreased mean arterial pressure and propranolol slightly increased this pressure. Both beta-blockers significantly increased systemic vascular resistance. From these observations, it was not possible to demonstrate that mepindolol offered a beneficial effect on splanchnic haemodynamics in patients with portal hypertension due to cirrhosis.
在两组各8例因肝硬化导致门静脉高压的患者中,研究了具有显著β2受体阻滞活性的β受体阻滞剂美多心安(0.6毫克,静脉注射)和普萘洛尔(15毫克,静脉注射)对内脏和全身血流动力学的影响。美多心安和普萘洛尔用药后,肝静脉压力梯度均有相似程度的下降,而美多心安用药后肝血流量显著减少,普萘洛尔用药后肝血流量则无显著减少。美多心安和普萘洛尔用药后心输出量和心率的下降具有统计学意义且相似。美多心安使平均动脉压略有下降,普萘洛尔使平均动脉压略有上升。两种β受体阻滞剂均显著增加全身血管阻力。从这些观察结果来看,无法证明美多心安对因肝硬化导致门静脉高压的患者的内脏血流动力学有有益作用。